Evidence map›Paper›PMID 18824712›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2008

Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.

Eric Raymond, Alba A Brandes, Christian Dittrich, Pierre Fumoleau, Bruno Coudert, Paul M J Clement, Marc Frenay, Roy Rampling, Roger Stupp, Johan M Kros and 5 more

Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00039364 (Open Label Phase II Study On STI571), which is not on this map. Cited by 97 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 6 pooled it
12.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00039364 phase2completednot on this map

Open Label Phase II Study On STI571 (Glivec) Administered As A Daily Oral Treatment In Gliomas

TypeinterventionalSponsorEuropean Organisation for Research and Treatment of Cancer - EORTCRan2002Enrolled112ConditionsBrain and Central Nervous System TumorsArmsimatinib mesylate
3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 6 syntheses or guidelines pooled it, 224 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2010
    Trial
  18. Trial
  19. Trial
  20. Trial

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Eric RaymondService Inter Hospitalier de Cancérologie, Beaujon University Hospital, Clichy.
Alba A Brandes
Christian Dittrich
Pierre Fumoleau
Bruno Coudert
Paul M J Clement
Marc Frenay
Roy Rampling
Roger Stupp
Johan M Kros
Michael C Heinrich
Thierry Gorlia
Denis Lacombe
Martin J van den Bent
European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
Neurological Surgery · US

Funding

EORTC HEADQUARTERSU10CA011488 · NCI · EUROPEAN ORG/RES/TREATMENT/CANCER · PI LACOMBE, DENIS · 1985 to 2015
$6.6M
NCI NIH HHS 5U10 CA11488-32NCI NIH HHS 5U10 CA11488-33NCI NIH HHS 5U10 CA11488-34
6 · The paper itself

Abstract

purposeTo evaluate the safety and the efficacy of imatinib in recurrent malignant gliomas. PATIENTS AND

methodsThis was a single-arm, phase II study. Eligible patients had recurrent glioma after prior radiotherapy with an enhancing lesion on magnetic resonance imaging. Three different histologic groups were studied: glioblastomas (GBM), pure/mixed (anaplastic) oligodendrogliomas (OD), and low-grade or anaplastic astrocytomas (A). Imatinib was started at a dose of 600 mg/d with dose escalation to 800 mg in case of no toxicity; during the trial this dose was increased to 800 mg/d with escalation to 1,000 mg/d. Trial design was one-stage Fleming; both an objective response and 6 months of progression-free survival (PFS) were considered a successful outcome to treatment.

resultsA total of 112 patients (51 patients with GBM, 25 patients with A, and 36 patients with OD) were enrolled. Imatinib was in general well tolerated. The median number of cycles was 2.0 (range, 1 to 43 cycles). Five patients had an objective partial response, including three patients with GBM; all had 6 months of PFS. The 6-month PFS rate was 16% (95% CI, 8.0% to 34.0%) in GBM, 4.0% (95% CI, 0.3% to 15.0%) in OD, and 9% (95% CI, 2.0% to 25.0%) in A. The exposure to imatinib was significantly lower in patients using enzyme-inducing antiepileptic drugs. The presence of ABCG2 point mutations were not correlated with pharmacokinetic findings. No somatic activating mutations of KIT or platelet-derived growth factor receptor-A or -B were found.

conclusionIn the dose range of 600 to 1,000 mg/d, single-agent imatinib is well tolerated but has limited antitumor activity in patients with recurrent gliomas.

Indexed as

AdultAgedAntineoplastic AgentsBenzamidesBrain NeoplasmsDisease-Free SurvivalDisease ProgressionFemaleGliomaHumansImatinib MesylateMagnetic Resonance ImagingMaleMiddle AgedNeoplasm Recurrence, LocalPiperazinesAntineoplastic AgentsBenzamidesImatinib MesylatePiperazinesPyrimidines

Identifiers

PMID18824712
PMCPMC2653126
OpenAlexW2061288640

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.